Pharmaceutical Business Review
Return to: PBR Home
Search Results:
1-15 of 56483 results
Biopharmaceutical firm Accent Therapeutics launches with $40m financing
By PBR Staff Writer
Accent Therapeutics has been launched with $40m Series A financing for precision cancer treatments targeting RNA-modifying proteins.
Drug Research > Drug Discovery & Development > News
Ipsen’s Cabometyx secures approval in Europe for first-line kidney cancer
The European Commission (EC) has approved Ipsen’s Cabometyx (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate or poor- risk advanced renal cell carcinoma (aRCC).
News
Pfizer’s Lyrica meets primary endpoint in phase 3 pediatric epilepsy trial
Pfizer has reported positive top-line results from a phase 3 study, which assessed the use of Lyrica (pregabalin) oral solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.
Contract Research & Services > Clinical Trials > News
Novartis and Amgen secure FDA approval for migraine drug
By PBR Staff Writer
Novartis and Amgen have secured approval from the US Food and Drug Administration (FDA) for Aimovig (erenumab), a treatment developed specifically for migraine prevention.
Regulatory Affairs > News
OptiBiotix Health signs manufacturing and supply deal in India with Akums
OptiBiotix Health has entered into a five year agreement with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply products featuring OptiBiotix's cholesterol and blood pressure reducing strain LPLDL in India.
Drug Research > Drug Delivery > News
IDMC recommends to expand Tiziana’s phase 2a trial of Milciclib
Tiziana Life Sciences announces that the independent data monitor committee (IDMC) completed a second, interim analysis of tolerability data from the first eleven treated patients and recommended expansion of the initial cohort to continue enrolment of an additional 20 patients to complete the trial.
Contract Research & Services > Clinical Trials > News
FDA declines to approve Evolus' DWP-450 for glabellar lines
By PBR Staff Writer
The US Food and Drug Administration (FDA) has declined to approve Evolus' application seeking approval of DWP-450 to treat glabellar lines in adult patients.
Regulatory Affairs > News
HiFiBiO Therapeutics raises $37.5m in Series B funding
By PBR Staff Writer
HiFiBiO Therapeutics has secured $37.5m Series B financing to accelerate pipeline of antibody drugs to treat cancer and autoimmune disorders.
Drug Research > Drug Discovery & Development > News
Surface Pharmaceuticals secures $20m funding from Flying L Partners
Surface Pharmaceuticals, an affiliated company of Imprimis Pharmaceuticals, has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of about $20m in a private placement of its Series A preferred stock.
Drug Research > Drug Discovery & Development > News
Novartis completes $8.7bn acquisition of AveXis
Novartis has completed its $8.7bn acquisition of US-based clinical stage gene therapy company AveXis via the consummation of a merger of its indirect wholly-owned subsidiary, Novartis AM Merger with and into AveXis.
Drug Research > Drug Discovery & Development > News
Meet SHL at BIO International Convention 2018
SHL Group, a world leader in device design and manufacturing, is proud to be participating in the 2018 BIO International Convention in Boston, Massachusetts from June 4-7. SHL will be at Booth #2525 to show its range of patient-friendly drug delivery solutions, which can accommodate any formulation for subcutaneous and intramuscular injection: low viscosity, high viscosity, high volume, unstable, and more. Representatives will also be on-site to introduce SHL’s turnkey solution, which leverages a full suite of in-house capabilities to take clients from device design to finished product distribution. Drawing over 16,000 participants from 5,000 companies last year, BIO International Convention is a premier biotech convention for industry partnering, education, and networking. SHL looks forward to connecting with top biotech and pharma companies and helping them meet their clinical and commercial needs. To learn more about our offering, visit at Booth #2525 at the Boston Convention & Exhibition Center. About SHL SHL is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as auto injectors and pen injectors. With locations in Taiwan, Sweden and the US, our experienced engineers and designers develop product enhancements and breakthrough drug delivery solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities. With over 3,700 staff worldwide, our organization consists of several distinct group companies: SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products For additional information visit www.shl.group SHL Media Contact info@shl-group.com
Press Releases

PBR Supplier Recommendations

CTL Laboratories - Contract Immune Monitoring and Research
Cellular Technology Limited (CTL), headquartered in Shaker Heights, OH, is a privately held biotechnology company that built its reputation as the global leader in the ELISPOT field over the past two decades by establishing the ELISPOT instrumentation and scientific principles that have helped to define the parameters of ELISPOT research for monitoring of Cell-Mediated Immunity.... Contract Research & Services > Clinical Trials > Suppliers
Persistence Market Research: Next-Gen Industry Insights & Growth Outlook
Persistence Market Research (PMR) is essentially a third-party research firm. Our model of research is a remarkable coordinated effort of information investigation and market look into procedure to enable organizations to accomplish ideal execution. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes. ... Suppliers
Future Market Insights: Global Industry Outlook & Business Review
FMI, catering to clients in more than 150 different countries, is a top-ranking provider of market intelligence and research. We are headquartered in the global financial capital, London and boast of some of the finest delivery centers in the U.S. and India. Our research and consulting experts have helped a multitude of businesses to manage their individual challenges in an aggressively evolving marketplace with great precision and boldness.... Suppliers
Transparency Market Research: In-depth Analysis, Accurate Results
Transparency Market Research (TMR) is a pioneer enterprise in the field of market research. We provide a plethora of services ranging from customized research, syndicated research, and consultation services. TMR’s worldwide and regional insights on the market cover industries such as chemicals, pharmaceuticals, media and technology, consumer goods, food and beverages, among others. Every deeply researched report from TMR offers its clients a panoramic vision of the market, its prognosis and statistical forecasts, a detailed segmentation, key ongoing trends, vendor landscape along with strategic recommendations.... Suppliers
Lohmann Therapy System (LTS) - Transdermal Therapeutic Systems and Oral Thin Films
LTS is the market leader in alternative drug delivery systems, in the form of transdermal therapeutic systems and oral thin films. We develop and manufacture drug delivery systems that offer patients reliable therapeutic efficacy with total comfort and convenience.... Drug Research > Drug Delivery > Suppliers
See more

PBR White Paper Recommendations

Improved-patient-safety-from-new-drug-delivery-device By Haselmeier
Clinical trials or industrial use of the self-injection system: The D-Flex Pen by Haselmeier is part of a brand new generation of drug delivery devices.... White Papers Malvern: Understanding and minimizing polycaprolactone degradation during processing using multi-detector GPC and rheology By Malvern Panalytical
Measuring degradation related changes in molecular weight and rheology during polycaprolactone processing... White Papers How Malvern Panalytical helped GSK India optimize their manufacturing process using By Malvern Panalytical
GSK India is headquartered at Worli, Mumbai with the manufacturing unit being located at Nashik. A second manufacturing facility at Vemgal, Karnataka is due to be completed in 2018.... White Papers Malvern: High sensitivity gel permeation chromatography for agrochemical analysis By Malvern Panalytical
Exploring why Syngenta opted for an OMNISEC system... White Papers Malvern: Measuring the rheology of thermoplastic polymer melts By Malvern Panalytical
Using rotational and capillary rheometry to characterize polymer melts... White Papers See more
1-15 of 56483 results